menu search

NVS / 4 High-Yield Dividend Aristocrat Retirement Dream Stocks

4 High-Yield Dividend Aristocrat Retirement Dream Stocks
This bear market has brought the worst first half for stocks since 1970. Market timing is proven to be the absolute worst strategy you can try, a 98% guaranteed road to underperformance or even financial ruin. Read More
Posted: Jul 2 2022, 13:30
Author Name: Seeking Alpha
Views: 111817

NVS News  

Novartis says drug candidate is successful in rare kidney disease trial

By Reuters
October 30, 2023

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney d more_horizontal

New And Improved Novartis

By Seeking Alpha
October 29, 2023

New And Improved Novartis

Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a dece more_horizontal

2 Green Flags and 1 Red Flag for Novartis Stock

By The Motley Fool
October 27, 2023

2 Green Flags and 1 Red Flag for Novartis Stock

Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates. more_horizontal

Novartis AG (NVS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 24, 2023

Novartis AG (NVS) Q3 2023 Earnings Call Transcript

Novartis AG (NYSE:NVS ) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relatio more_horizontal

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

By Zacks Investment Research
October 24, 2023

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income. more_horizontal

Novartis Raises Outlook After Sandoz Generics Spinoff

By Bloomberg Markets and Finance
October 24, 2023

Novartis Raises Outlook After Sandoz Generics Spinoff

Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a more_horizontal

Novartis Begins New Era With Profit Beat and Guidance Hike

By Barrons
October 24, 2023

Novartis Begins New Era With Profit Beat and Guidance Hike

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its more_horizontal

Novartis lifts 2023 earnings forecast for third time

By Reuters
October 24, 2023

Novartis lifts 2023 earnings forecast for third time

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun o more_horizontal


Search within

Pages Search Results: